AMARIN CORPORATION PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.8525 USD | -3.12% |
|
-6.32% | -2.01% |
Presentation Operator MessageOperator (Operator)Welcome to Amarin Corporation’s conference cal...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Amarin Corporation PLC is a pharmaceutical company. The Company is focused on the commercialization and development of therapeutics to improve cardiovascular (CV), health and reduce CV risk. The Company operates through the development and commercialization of VASCEPA. Its lead product, Vascepa (icosapent ethyl) capsule is used as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. This indication for Vascepa, known as the MARINE indication, is based primarily on the results from the MARINE study of Vascepa in this approved patient population. The Company sells Vascepa principally to wholesalers, as well as selected regional wholesalers and specialty pharmacy providers, or collectively, its distributors, which in turn resell Vascepa to retail pharmacies for resale to patients and healthcare providers.
Calendar
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
HOLD
Number of Analysts
3
Last Close Price
0.8525
USD
Average target price
1
USD
Spread / Average Target
+17.30%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -2.01% | 350M | |
| +3.91% | 109B | |
| +10.87% | 105B | |
| +1.28% | 22.25B | |
| -13.14% | 22.09B | |
| -7.05% | 18.68B | |
| -38.36% | 17.58B | |
| -10.66% | 16.85B | |
| +3.75% | 13.76B | |
| +36.70% | 12.46B |
- Stock Market
- Equities
- AMRN Stock
- News Amarin Corporation plc
- Transcript : Amarin Corporation plc, Q1 2022 Earnings Call, May 04, 2022